close
close
awsum

Report reveals China targets AstraZeneca in cancer treatment fraud investigation

Neon
Report reveals China targets AstraZeneca in cancer treatment fraud investigation

Pharmaceutical giant AstraZeneca, whose chairman is China under investigationIt had previously been investigated for health insurance fraud cases involving the sale of cancer drugs, according to new Chinese media reports.
The news appeared on the British-Swedish company’s official website last week. Chinese chef Leon Wang It was cooperating with an “ongoing investigation” and its operations in the country would continue under the leadership of AstraZeneca China’s chief executive.
Media outlet Caixin reported on Monday that an official investigation, first made public in early 2022, targeted sales representatives of AstraZeneca’s lung cancer drug. Tagrisso in the southern city of Shenzhen.
The National Health Security Administration (NHSA), which oversees China’s overall health situation health insurance plan and medical assistance programs announced on January 29, 2022, that some AstraZeneca employees were suspected of defrauding health insurance companies by altering cancer patients’ genetic test results, allowing them to purchase drugs using insurance.

In this statement, NHSA said it had formed a task force to investigate and arrested all suspects. However, the institution did not disclose the identities of the suspects or the drugs used.

Caixin reported that Zuo Yinquan, who was responsible for the sales of cancer drugs, including Tagrisso, in Guangdong, Hunan, Yunnan and Hainan provinces and Guangxi Zhuang autonomous region, was arrested by Shenzhen police on January 8, 2022.

This was the beginning of a series of insurance fraud cases involving the company, according to the report. In June 2022, several of the company’s employees in Fujian were detained by police, and in September that year, AstraZeneca’s Fujian general manager Kang Yuling was arrested.

Related Posts